LTC2662091I2 - Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui - Google Patents

Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Info

Publication number
LTC2662091I2
LTC2662091I2 LTPA2021506C LTPA2021506C LTC2662091I2 LT C2662091 I2 LTC2662091 I2 LT C2662091I2 LT PA2021506 C LTPA2021506 C LT PA2021506C LT PA2021506 C LTPA2021506 C LT PA2021506C LT C2662091 I2 LTC2662091 I2 LT C2662091I2
Authority
LT
Lithuania
Prior art keywords
treatment
inflammatory diseases
selectin antibodies
selectin
antibodies
Prior art date
Application number
LTPA2021506C
Other languages
English (en)
Original Assignee
Novartis Ag
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Oklahoma Medical Research Foundation filed Critical Novartis Ag
Publication of LTPA2021506I1 publication Critical patent/LTPA2021506I1/lt
Publication of LTC2662091I2 publication Critical patent/LTC2662091I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTPA2021506C 2006-12-01 2021-04-13 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui LTC2662091I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87217006P 2006-12-01 2006-12-01
EP07867601A EP2097105A4 (en) 2006-12-01 2007-11-30 ANTI-P SELEKTIN ANTIBODIES AND METHOD FOR THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
PCT/US2007/024692 WO2008069999A2 (en) 2006-12-01 2007-11-30 Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases

Publications (2)

Publication Number Publication Date
LTPA2021506I1 LTPA2021506I1 (lt) 2021-05-10
LTC2662091I2 true LTC2662091I2 (lt) 2022-10-10

Family

ID=39492818

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13164403.1T LT2662091T (lt) 2006-12-01 2007-11-30 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
LTPA2021506C LTC2662091I2 (lt) 2006-12-01 2021-04-13 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13164403.1T LT2662091T (lt) 2006-12-01 2007-11-30 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Country Status (11)

Country Link
US (2) US8377440B2 (lt)
EP (3) EP2097105A4 (lt)
CY (2) CY1121072T1 (lt)
DK (1) DK2662091T3 (lt)
ES (1) ES2699273T3 (lt)
HU (3) HUE041957T2 (lt)
LT (2) LT2662091T (lt)
PL (1) PL2662091T3 (lt)
PT (1) PT2662091T (lt)
SI (1) SI2662091T1 (lt)
WO (1) WO2008069999A2 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041957T2 (hu) 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
EP2654781B1 (en) * 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
EP3019203A4 (en) 2013-07-09 2017-04-26 President and Fellows of Harvard College Endothelial cell genes and uses thereof
WO2015006501A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US20200087403A1 (en) 2017-03-15 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
AU2018265261B2 (en) * 2017-05-10 2025-05-22 Inovio Pharmaceuticals, Inc. Optimized nucleic acid antibody constructs
JP2020524283A (ja) 2017-06-20 2020-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 急性非代償性心不全（ａｄｈｆ）患者が凝固亢進状態を示すかどうかを同定するための方法
CN107299112A (zh) * 2017-06-22 2017-10-27 广东药科大学 一种炎症分子（psgl‑1）缺失的脂代谢异常模型的构建及其应用
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
CA3092931A1 (en) 2018-03-08 2019-09-12 Novartis Ag Use of an anti-p-selectin antibody
US20220306749A1 (en) 2019-06-07 2022-09-29 Novartis Ag Use of an Anti-P-selectin Antibody
WO2021010937A1 (en) 2019-07-17 2021-01-21 Emmaus Medical, Inc. Methods and compositions for the treatment of sickle cell diseases and thalassemia
AU2020326490A1 (en) * 2019-08-08 2022-03-24 Novartis Ag Use of the anti-P-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
TWI893018B (zh) 2019-10-30 2025-08-11 瑞士商諾華公司 抗體配製物
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
JP7846007B2 (ja) 2019-12-18 2026-04-14 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0606391B1 (en) 1991-09-30 1998-08-05 Biogen, Inc. Inhibition of vascular narrowing using anti-padgem antibodies
JPH07506253A (ja) 1992-04-30 1995-07-13 ジェネンテク，インコーポレイテッド セレクチン変異体
DK0642356T3 (da) * 1992-05-05 2003-08-04 Aeres Biomedical Ltd Antistoffer mod P-selectin og deres anvendelser
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
EP0804235A4 (en) 1993-05-04 2001-09-19 Aeres Biomedical Ltd ANTIBODIES AGAINST P-SELECTIN AND THEIR USE
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
DE69534761T2 (de) * 1994-06-03 2006-10-12 The CBR Institute for Biomedical Reserach, Inc., Boston Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
DE60118362T2 (de) 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
TWI335821B (en) * 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
HUE041957T2 (hu) * 2006-12-01 2019-06-28 Novartis Ag Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US7833530B2 (en) 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
EP2654781B1 (en) 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification

Also Published As

Publication number Publication date
CY2021009I1 (el) 2021-10-15
PT2662091T (pt) 2018-12-03
US20110243926A1 (en) 2011-10-06
HUS2100015I1 (hu) 2021-05-28
CY2021009I2 (el) 2021-12-31
EP2097105A4 (en) 2010-09-15
PL2662091T3 (pl) 2019-05-31
WO2008069999A3 (en) 2008-12-04
LTPA2021506I1 (lt) 2021-05-10
US20140072551A1 (en) 2014-03-13
LT2662091T (lt) 2018-12-10
CY1121072T1 (el) 2019-12-11
HUE041957T2 (hu) 2019-06-28
DK2662091T3 (en) 2018-12-17
HUS2100011I1 (hu) 2021-05-28
EP2662091B1 (en) 2018-08-22
ES2699273T3 (es) 2019-02-08
EP2662091A3 (en) 2014-03-12
EP2662091A2 (en) 2013-11-13
WO2008069999A2 (en) 2008-06-12
EP3501538A1 (en) 2019-06-26
SI2662091T1 (sl) 2019-01-31
US8377440B2 (en) 2013-02-19
EP2097105A2 (en) 2009-09-09
US9556266B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
LTC2662091I2 (lt) Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
LTPA2020523I1 (lt) Anti-CD79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
LTC2152290I2 (lt) Anti-il-5 antikūnų skyrimo būdai
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
CY2017039I2 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
CR10679A (es) Novel anti-cd38 antibodies for the treatment of cancer
EP2010216A4 (en) MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
FI20075738L (fi) Elimen valaiseminen
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
EP2154148A4 (en) SHORTENED L1 PROTEIN OF THE HUMAN PAPILLOMA VIRUS 11
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
DK2328553T3 (da) Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
DK2182007T3 (da) Fremgangsmåde til fremstilling af humant G-CSF
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
EP2281575A4 (en) ANTIBODIES FOR THE TREATMENT OF CANCER
FI20085333L (fi) Aktuaattorin äänikentän suuntaaminen
DK2224934T3 (da) Anvendelse af osteoblaster til behandling af inflammatoriske rheumatiske sygdomme
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases